Market News / Story
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
GlobeNewswire ·
GlobeNewswire reports: Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol WOBURN, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that it has submitted a supplemental New…